Brain Tumours

A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM). 2014 ASCO Annual Meeting • Antibody targeting EGFR or mutant EGFRvIII conjugated to a cytotoxic anti- microtubule agent • Preclinical activity against GBM tumor models - either amplified wild type EGFR or EGFRvIII • Preliminary safety data demonstrate unique toxicity - corneal epithelial microcysts • Preliminary responses in 3/9 pts with TMZ refractory GBM; 1 CR • Phase 2 studies of ABT-414 in GBM underway: – With TMZ in recurrent GBM (EGFR amplified or EGFRvIII mutated) – With RT-TMZ in first line GBM (EGFR amplified or EGFRvIII mutated)